GordonMD, an investment company, and Pfizer Ventures, a corporate venture capital firm, led a $123m Series B funding round in Flare Therapeutics, a biotech startup, with participation from Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest, Third Rock Ventures, Agent Capital, Eli Lilly and Company, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital and ShangBay Capital. "Flare has taken on one of the most formidable challenges in drug discovery – drugging transcription factors. The company is making impressive strides enabled by its platform, which to date has successfully identified more than 150 switch sites across the majority of transcription factor families, providing opportunities to treat a broad range of diseases," Craig D. Gordon, GordonMD CEO and CIO.